Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy
Restricted accessResearch articleFirst published online 2026
Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy
To treat patients affected with bestrophinopathies caused by mutations in the BEST1 gene, a recombinant adeno-associated virus vector (OPGx-BEST1 or rAAV2/2-VMD2-BEST1) is being developed. The vector construct includes the human BEST1 cDNA under control of the VMD2/BEST1 promoter and is packaged in an AAV2 capsid. This study evaluated the efficacy and toxicity of OPGx-BEST1 administered by subretinal injection in dogs that were homozygous mutant or compound heterozygotes for 3 naturally occurring mutations in BEST1. Twelve BEST1-mutant dogs were divided into 4 groups of 3 animals each, and they received in their left eye a subretinal injection of 0.15 mL of OPGx-BEST1 at 1 of 3 concentrations (9.5 × 109 vector genome [vg]/mL; 3.0 × 1010 vg/mL; or 3.0 × 1011 vg/mL) of OPGx-BEST1, resulting, respectively, in a low (1.4 × 109 vg), high (4.5 × 109 vg), and highest (4.5 × 1010 vg) dose or vehicle control. The right eyes were not injected. Subretinal injections were well tolerated and were not associated with any systemic or ocular toxicity. Electroretinography showed improved rod- and cone-mediated responses in eyes treated with OPGx-BEST1. Noninvasive retinal imaging by optical coherence tomography showed improved structural integrity with a reduction or prevention of appearance of vitelliform lesions and reversal of microdetachments in the retinal areas treated with OPGx-BEST1. These results support the use of OPGx-BEST1 in clinical studies with patients affected with bestrophinopathies and define the no-observed-adverse-effect level at 4.5 × 1010 vg/eye (0.15 mL, 3.0 × 1011 vg/mL).
MarmorsteinAD, MarmorsteinLY, RaybornM, et al.Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A2000;97(23):12758–12763.
2.
StraussO. The retinal pigment epithelium in visual function. Physiol Rev2005;85(3):845–881.
3.
SunH, TsunenariT, YauKW, et al.The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A2002;99(6):4008–4013.
4.
GómezNM, TammER, StrauβO. Role of bestrophin-1 in store-operated calcium entry in retinal pigment epithelium. Pflugers Arch2013;465(4):481–495.
5.
JohnsonAA, GuziewiczKE, LeeCJ, et al.Bestrophin 1 and retinal disease. Prog Retin Eye Res2017;58:45–69.
6.
RosenthalR, BakallB, KinnickT, et al.Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. Faseb J2006;20(1):178–180.
7.
HartzellHC, QuZ, YuK, et al.Molecular physiology of bestrophins: Multifunctional membrane proteins linked to best disease and other retinopathies. Physiol Rev2008;88(2):639–672.
8.
StraußO, MüllerC, ReichhartN, et al.The role of bestrophin-1 in intracellular Ca(2+) signaling. Adv Exp Med Biol2014;801:113–119.
9.
Kane DicksonV, PediL, LongSB. Structure and insights into the function of a Ca(2+)-activated Cl(-) channel. Nature2014;516(7530):213–218.
10.
YangT, LiuQ, KlossB, et al.Structure and selectivity in bestrophin ion channels. Science2014;346(6207):355–359.
11.
YangT, JustusS, LiY, et al.BEST1: The Best Target for Gene and Cell Therapies. Mol Ther2015;23(12):1805–1809.
12.
MilenkovicA, BrandlC, MilenkovicVM, et al.Bestrophin 1 is indispensable for volume regulation in human retinal pigment epithelium cells. Proc Natl Acad Sci U S A2015;112:E2630–E2639.
13.
PetrukhinK, KoistiMJ, BakallB, et al.Identification of the gene responsible for Best macular dystrophy. Nat Genet1998;19(3):241–247.
14.
SeddonJM, AfshariMA, SharmaS, et al.Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull’s-eye maculopathy. Ophthalmology2001;108(11):2060–2067.
15.
YardleyJ, LeroyBP, Hart-HoldenN, et al.Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci2004;45(10):3683–3689.
16.
SchatzP, KlarJ, AndreassonS, et al.Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet2006;27(2):51–56.
17.
BurgessR, MillarID, LeroyBP, et al.Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet2008;82(1):19–31.
18.
DavidsonAE, MillarID, UrquhartJE, et al.Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. Am J Hum Genet2009;85(5):581–592.
19.
BoonCJ, KleveringBJ, LeroyBP, et al.The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res2009;28(3):187–205.
20.
BestF. Uber eine hereditare Maculaaffektion. Z Augenheilk1905;13:199–212.
21.
GassJDM. Best’s Disease. In: Stereoscopic Atlas of Macular Diseases: A Funduscopic and Angiographic Presentation. C.V. Mosby Co., St. Louis, MO; 1997; pp. 304–311.
22.
PiantaMJ, AlemanTS, CideciyanAV, et al.In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res2003;76(2):203–211.
23.
BitnerH, SchatzP, Mizrahi-MeissonnierL, et al.Frequency, genotype, and clinical spectrum of best vitelliform macular dystrophy: Data from a national center in Denmark. Am J Ophthalmol2012;154(2):403–412.e4. e404.
24.
PasquayC, WangLF, LorenzB, et al.Bestrophin 1–Phenotypes and Functional Aspects in Bestrophinopathies. Ophthalmic Genet2015;36(3):193–212.
25.
CideciyanAV, JacobsonSG, SwiderM, et al.Photoreceptor function and structure in autosomal dominant vitelliform macular dystrophy caused by BEST1 mutations. Invest Ophthalmol Vis Sci2022;63(13):12.
26.
BakallB, RaduRA, StantonJB, et al.Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res2007;85(1):34–43.
27.
YuK, QuZ, CuiY, et al.Chloride channel activity of bestrophin mutants associated with mild or late-onset macular degeneration. Invest Ophthalmol Vis Sci2007;48(10):4694–4705.
28.
GuziewiczKE, SlavikJ, LindauerSJ, et al.Molecular consequences of BEST1 gene mutations in canine multifocal retinopathy predict functional implications for human bestrophinopathies. Invest Ophthalmol Vis Sci2011;52(7):4497–4505.
29.
DunckerT, GreenbergJP, RamachandranR, et al.Quantitative fundus autofluorescence and optical coherence tomography in best vitelliform macular dystrophy. Invest Ophthalmol Vis Sci2014;55(3):1471–1482.
30.
GuziewiczKE, SinhaD, GomezNM, et al.Bestrophinopathy: An RPE-photoreceptor interface disease. Prog Retin Eye Res2017;58:70–88.
31.
GuziewiczKE, CideciyanAV, BeltranWA, et al.BEST1 gene therapy corrects a diffuse retina-wide micro-detachment modulated by light exposure. Proc Natl Acad Sci U S A2018;115:E2839–E2848.
32.
Koushik TripathyBS. Best Disease. StatPearls Publishing; 2023.
33.
CideciyanAV, JacobsonSG, SumarokaA, et al.Photoreceptor function and structure in retinal degenerations caused by biallelic BEST1 mutations. Vision Res2023;203:108157.
34.
AguirreGD, BeltranWA. Canine Best disease as a translational model. Eye (Lond)2025;39(3):412–417.
35.
BeltranWA, CideciyanAV, GuziewiczKE, et al.Canine retina has a primate fovea-like bouquet of cone photoreceptors which is affected by inherited macular degenerations. PLoS One2014;9(3):e90390.
36.
WuV, SwiderM, SumarokaA, et al.Retinal response to light exposure in BEST1-mutant dogs evaluated with ultra-high resolution OCT. Vision Res2024;218:108379.
37.
BeltranWA, CideciyanAV, IwabeS, et al.Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci U S A2015;112(43):E5844–E5853.
38.
DufourVL, CideciyanAV, YeGJ, et al.Toxicity and efficacy evaluation of an adeno-associated virus vector expressing codon-optimized RPGR delivered by subretinal injection in a canine model of X-linked Retinitis Pigmentosa. Hum Gene Ther2020;31(3–4):253–267.
39.
YehiaS, AbdouO, KelanyM, et al.Ultrasonographic, morphologic and biochemical alterations in experimentally induced steroid hepatopathy in dogs. Glob Vet2013;11:123–130.
40.
HallRL, EverdsNE. Factors affecting the interpretation of canine and nonhuman primate clinical pathology. Toxicol Pathol2003;31 Suppl:6–10.
41.
AktasM, AugusteD, LefebvreHP, et al.Creatine kinase in the dog: A review. Vet Res Commun1993;17(5):353–369.
42.
WolleyR, BlundellR, ElseR, et al.Atrial myocarditis as a cause of sinus arrest in a dog. J Small Anim Pract2007;48:455–457.
43.
MauriziN, AmmiratiE, SilverE, et al.Incidence, timing and clinical significance of immune-mediated myocardial injury and myocarditis after gene replacement therapy: A systematic review and meta-analysis. Circ Heart Fail2026;19(5):e013771.
44.
AliRR, ReichelMB, ThrasherAJ, et al.Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet1996;5(5):591–594.
45.
FlanneryJG, ZolotukhinS, VaqueroMI, et al.Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A1997;94(13):6916–6921.
46.
AclandGM, AguirreGD, RayJ, et al.Gene therapy restores vision in a canine model of childhood blindness. Nat Genet2001;28(1):92–95.
47.
LuQ, WrightA, PanZH. AAV dose-dependent transduction efficiency in retinal ganglion cells and functional efficacy of optogenetic vision restoration. Gene Ther2024;31(11–12):572–579.
48.
AmadoD, MingozziF, HuiD, et al.Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med2010;2(21):21ra16.
49.
AnnearMJ, BartoeJT, BarkerSE, et al.Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther2011;18(1):53–61.
50.
BennettJ, AshtariM, WellmanJ, et al.AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med2012;4(120):120ra15.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
